Skip to main content

Adocia S.A. (ADOIF)

OTC Markets (US) Healthcare BiotechnologyView data quality →
29.9Poor

ValueMarkers Composite Index

Top 0%#44,643 of 44,714

DCF data not available

Piotroski
3/9
Weak
Beneish
5.00
High Risk
Altman
-1.79
Distress
DCF Value
-
N/A
ROIC
-61.9%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Adocia S.A. (ADOIF) — VMCI valuation read

Headline read on ADOIF: VMCI of 30/100 versus a Healthcare sector median of 50. The 20-point below-median position is what makes Adocia S.A. a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on ADOIF: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on ADOIF: value (ADOIF trades at 21.0x earnings, 17% above the Healthcare median of 18.0x), quality (ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 0.0x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

ADOIF fell 0.5% over the trailing 7 days, with a -0.5% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in ADOIF’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.